11,407 Shares in Illumina, Inc. $ILMN Acquired by Inscription Capital LLC

Inscription Capital LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,407 shares of the life sciences company’s stock, valued at approximately $1,083,000.

Other hedge funds have also modified their holdings of the company. WCM Investment Management LLC raised its position in shares of Illumina by 5.9% during the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after purchasing an additional 247,460 shares during the period. Loomis Sayles & Co. L P grew its position in Illumina by 1.9% in the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after acquiring an additional 78,317 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Illumina by 55.3% in the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after acquiring an additional 1,174,295 shares during the period. Geode Capital Management LLC raised its holdings in shares of Illumina by 0.7% in the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after buying an additional 21,342 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Illumina by 1.9% during the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after buying an additional 35,167 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Robert W. Baird set a $109.00 price objective on Illumina in a research note on Friday, October 31st. JPMorgan Chase & Co. raised their price target on shares of Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday. Guggenheim raised their price objective on Illumina from $114.00 to $144.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Stifel Nicolaus upped their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $124.47.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Scott Gottlieb acquired 500 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.17% of the stock is currently owned by corporate insiders.

Illumina Trading Up 3.9%

ILMN opened at $147.17 on Wednesday. The stock has a market capitalization of $22.49 billion, a PE ratio of 33.00, a P/E/G ratio of 2.35 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina, Inc. has a one year low of $68.70 and a one year high of $151.34. The business’s 50 day moving average price is $133.32 and its 200 day moving average price is $112.20.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter last year, the company posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.